FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  2. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  3. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  4. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  5. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  6. Medline Inc

    FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

    High risk
  7. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  8. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  9. Chemco Corporation

    FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.

    High risk
  10. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  11. Tentamus India Private Limited

    FDA warned India-based contract testing lab Tentamus over destroyed and backdated lab records and limited inspection access.

    High risk
  12. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk